Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : $2,900.0 million
Deal Type : Acquisition
Sanofi Completes Acquisition of Provention Bio, Inc.
Details : Through the acquisition of Provention Bio, Sanofi adds to its portfolio, TZIELD (teplizumab-mzwv), a CD3-directed antibody, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).
Product Name : Tzield
Product Type : Antibody
Upfront Cash : $2,900.0 million
April 27, 2023
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : $2,900.0 million
Deal Type : Acquisition
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : $2,900.0 million
Deal Type : Acquisition
Details : Through the acquisition of Provention Bio, Sanofi adds to its portfolio, TZIELD (teplizumab-mzwv), a CD3-directed antibody, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).
Product Name : Tzield
Product Type : Antibody
Upfront Cash : $2,900.0 million
March 13, 2023
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : $2,900.0 million
Deal Type : Acquisition
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : $35.0 million
Deal Type : Agreement
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
Details : The financing will be used to support the commercial launch of TZIELD (teplizumab-mzwv). TZIELD is a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D.
Product Name : Tzield
Product Type : Antibody
Upfront Cash : Undisclosed
February 13, 2023
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : $35.0 million
Deal Type : Agreement
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Hercules Capital
Deal Size : Undisclosed
Deal Type : Financing
Details : Tzield (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D.
Product Name : Tzield
Product Type : Antibody
Upfront Cash : Undisclosed
February 02, 2023
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Hercules Capital
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Provention Bio
Deal Size : Undisclosed
Deal Type : Agreement
AGC Biologics to Commercial Manufacture Provention Bio Diabetes Therapy
Details : Under the agreement, AGC Biologics will manufacture TZIELD™ (teplizumab-mzwv), a new T1D treatment. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older.
Product Name : Tzield
Product Type : Antibody
Upfront Cash : Undisclosed
January 24, 2023
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Provention Bio
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : $20.0 million
Deal Type : Acquisition
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
Details : Through the acquisition, Ligand acquires royalty on Sanofi’s Tzield (teplizumab-mzwv), the first disease-modifying therapy in type 1 diabetes and a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and children aged 8 years an...
Product Name : Tzield
Product Type : Antibody
Upfront Cash : $20.0 million
January 11, 2023
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : $20.0 million
Deal Type : Acquisition
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Provention Bio
Deal Size : $395.0 million
Deal Type : Agreement
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
Details : Under the terms of the agreements held in 2018, Provention has acquired all rights to Tzield (teplizumab) to be further developed as PRV-031 and licensing rights to MGD010 for development as PRV-3279.
Product Name : Tzield
Product Type : Antibody
Upfront Cash : Undisclosed
November 17, 2022
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Provention Bio
Deal Size : $395.0 million
Deal Type : Agreement
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes
Details : Tzield (teplizumab-mzwv) binds to certain immune system cells and delays progression to stage 3 type 1 diabetes. Tzield may deactivate the immune cells that attack insulin-producing cells, while increasing the proportion of cells that help moderate the i...
Product Name : Tzield
Product Type : Antibody
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : JDRF
Deal Size : $0.6 million
Deal Type : Partnership
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
Details : The JDRF award will fund efforts to investigate the use of NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab. The investigation will test this hypothesis in a preclinical model by combining anti-CD3 mAb treatment.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
October 05, 2022
Lead Product(s) : Undisclosed,Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : JDRF
Deal Size : $0.6 million
Deal Type : Partnership
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Sanofi
Deal Size : $55.0 million
Deal Type : Agreement
Details : Teplizumab (PRV-031), is an investigational anti-CD3 monoclonal antibody that is being evaluated for the delay of clinical type 1 diabetes (T1D) in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies.
Product Name : Tzield
Product Type : Antibody
Upfront Cash : $20.0 million
June 10, 2022
Lead Product(s) : Teplizumab
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Sanofi
Deal Size : $55.0 million
Deal Type : Agreement